The effects of the angiotensin converting enzyme (ACE) inhibitor captopril and the neutral endopeptidase (NEP) inhibitors thiorphan and SCH 32615 on the changes in airway opening pressure (Pao) and the recovery of offered peptide were studied after intratracheal administration of substance P (SP) and neurokinin A (NKA) in isolated guinea pig lungs superfused through the trachea. Pao changes and the recovery of offered peptide were significantly greater in NEP inhibitor-treated lungs than in control lungs. Captopril did not cause a significant change in the physiological effects or the recovery of SP and NKA. HPLC analysis of I3H]Pro2'4-SP and '25I-Histidyl'-NKA perfused through the airways showed major cleavage products consistent with NEP action. We conclude that there is significant degradation of both SP and NKA after tracheal infusion of peptides by NEP-like but not by ACE activity; this effect significantly influences the physiological effects of these peptides. (J. Clin. Invest. 1990. 85:170-176.) EC 3.4.24.11-neuropeptides * tachykinins
Introduction
Substance P (SP)' and neurokinin A (NKA) are two small structurally related bioactive peptides found in certain sensory nerves in the lung (1, 2) . These peptides are known to transduce a variety of biological effects in the lung including the stimulation of mucus secretion (3, 4) , the promotion of active epithelial chloride transport (5), enhanced vascular permeability (6, 7) , and airway smooth muscle contraction (8) (9) (10) . Although these peptides are extremely potent biomolecules, their physiological effects in vitro and in vivo appear to be limited by their rapid degradation at or near the site of their release (1 1-14) . SP can be degraded by several peptidases, including neutral endopeptidase (EC 3.4.24.1 1, NEP) (15, 16) and an-1. Abbreviations used in this paper: ACE, angiotensin converting enzyme; NEP, neutral endopeptidase; NKA, neurokinin A; Pao, airway opening pressure; SCH 32615, (N-[L4-(I-carboxy-2-phenyl)ethyl]-Lphenylalanyl-B-alanine); SP, substance P; TCBLCB, thiorphan, captopril, bestatin, leupeptin, chymostatin, and bacitracin.
giotensin converting enzyme (EC 3.14.5.1, ACE) (17, 18, 19) . NKA is also known to be a substrate for NEP (20) but not lung ACE (21) .
Although these peptides are subject to degradation by NEP and ACE, the relative importance of these degradative mechanisms in limiting airway effects is also regulated by the locus of the catabolizing enzyme relative to the site ofpeptide administration or release. For example when SP is administered to guinea pigs by the vascular route its activity is controlled by both ACE and NEP (22, 23) . When SP is administered by aerosol, NEP inhibitors enhance its bronchoconstrictor activity (24) ; the effects of ACE inhibitors on this response are not known. Since NEP is predominantly an epithelial enzyme, whereas ACE is an endothelial one (25) , we reasoned that ACE would not be important in modulating the effects of tachykinins after administration via the airways. In order to test this hypothesis we used the airway superfused lung preparation of Nucci and Moncada (26) .
Methods
Tracheal perfusion. 120 male Hartley strain guinea pigs, 240-430 g body wt, were anesthetized with sodium pentobarbital (65 mg/kg i.p.), tracheostomized, and the abdominal wall was opened to expose the aorta and vena cava. Heparin (500 U) was infused into the vena cava and 3 min later the abdominal aorta was cut. The thoracic wall was removed and the heart and lungs removed en bloc. The lungs were placed in a plexiglass box, kept at 37°C and 100% relative humidity, and the tracheal cannula was connected to a perfusion system (see below). The lungs were superfused with a phosphate-buffered physiological solution whose composition was NaCI 137 mM, CaCl2 1.8 mM, MgCl2 1.05 mM, KC1 2.68 mM, NaHCO3 0.06 mM, NaH2PO4 0.13 mM, and Na2HPO4 0.869 mM, pH 7.4. The perfusion fluid was warmed to 45°C outside the plexiglass box to drive excess gas from it, then cooled to 37°C and passed through a bubble trap before entering the lungs via the trachea. The perfusion rate was 5 ml/min. The perfusate was allowed to leave the lungs through numerous small holes made in the pleural surface with a 25-gauge needle and collected in plastic tubes containing ice-cold glacial acetic acid such that the final concentration of acetic acid in each fraction was 5% by volume. There was a side tap at the end of the tracheal cannula that was connected to a pressure transducer (P23Db; Statham Instruments, Inc., Oxnard, CA) for measurement of airway opening pressure (Pao).
Assay ofsubstance P and neurokinin A. SP and NKA levels in the perfusate were measured by a solid phase enzyme linked immunosorbent assay (ELISA). The ELISA for SP was performed as described by Folkersson et al. (27) using commercially available antiserum. The lower limit of detection was 3 fmol of SP; we found < 0.01% cross-reactivity with substance P 1-6, substance P 1-9 or NKA.
The ELISA for NKA was performed with minor modifications of the technique used to measure SP. Specifically the solutions to be assayed were incubated with the antibody at 4°C for 44-50 h and transferred to microtiter plates previously cooled to 4°C. The Experimental protocols Protocol 1. In the first protocol dose-response curves of SP, NKA, and methacholine were constructed. After the lungs were placed in the perfusion apparatus, a period of 15-20 min was allowed for the lungs to equilibrate. Doses of 1, 10, or 100 pmol ofeither SP or NKA diluted in 100 ,1A of perfusion buffer were rapidly injected into the tracheal perfusate; only one dose of peptide was given to each lung (n = 3 for each dose/peptide). To construct the methacholine dose-response curves three separate lungs were studied. In these studies doses of0.01, 0.1, 1, and 10 nmol ofmethacholine each diluted in 100 Ml ofperfusion buffer were infused into the trachea. Sufficient time was allowed before the first dose to achieve a stable baseline pressure and between successive doses for tracheal perfusion pressure to return near to baseline conditions. We also studied the effects of tracheal infusion of doses of 1, 10, and 100 nmol of NKA 1-8 and SP 1-9 (three lungs for each peptide).
Protocol 2. In the second protocol the effects of various enzyme inhibitors (see below) on airway pressure and peptide recovery after tracheal administration of SP and NKA was examined. 10-15 min after the lungs were placed in the perfusion system the buffer was changed to contain either: (a) no enzyme inhibitors (control); (b) captopril 3 MM; (c) thiorphan 1 MM; (d) SCH 32615 10MM; (e) a combination of thiorphan 1 MM, captopril 3 MM, bestatin 1 MM, leupeptin 4 Mg/ml, chymostatin 4 Mg/ml, and bacitracin 100 Mg/ml (TCBLCB). After 10-15 min more of perfusion under one of these five conditions, 10 pmol ofeither SP or NKA in 100 Ml ofperfusion buffer was administered as in protocol 1. The perfusate was collected for 15 min to measure SP and NKA recovery. Five lungs were studied under each condition. To establish recoveries in the absence of peptide metabolism on two occasions 10 pmol of either SP and NKA was passed through the perfusion system alone. The peptides were collected and processed as described above; this value was taken as 100% recovery. and '25I-Histidyl'NKA was studied. 1.2 X 106 cpm of3H-SP or 2 X l0' cpm of 125I44VA together with 10 pmol of the corresponding nonlabeled peptide was infused into the trachea under the same five experimental conditions described in protocol 2 above; three lungs were studied under each condition. The perfusate was collected after the infusion of peptide in five fractions corresponding to periods of 0-1, 1-2.5, 2.5-5, 5-10, and 10-15 min after injection of SP or NKA.
Materials. SP, SP fragments (1-6, 1-7, and 1-9), SP antisera and NKA antisera were acquired from Peninsula Laboratories, Belmont, CA. Bacitracin, leupeptin, chymostatin, bestatin, and methacholine chloride were purchased from Sigma Chemical, St. perfused with a buffer with SCH 32615 10 1M (15.48±1.59 cm H20) (n = 5 for each group of lungs).
The recovery of peptides in the perfusate collected for 15 min after tracheal infusion of SP or NKA as determined by ELISA is shown in Figs. 3 and 4 , respectively. Both thiorphan and SCH 32615 led to a significant increase in SP and NKA recovery (P < 0.025 and P < 0.001 for SP and P < 0.05 and P < 0.025 for NKA, respectively). The addition of other peptidase inhibitors to thiorphan, i.e., TCBLCB, did not result in recovery values significantly higher than thiorphan alone when either SP or NKA was the offered peptide. Captopril pretreatment did not result in a significant increase in SP or NKA recovery values compared with lungs not treated with enzyme inhibitors.
Similar relative recoveries of SP and NKA were obtained when the radiolabeled moieties were used to monitor peptide recovery. 89.7±0.76% and 90.9±0.99% of the recovered label, respectively, for SP and NKA were present in the perfusate corresponding to the first 5 min of perfusion after the infusion of peptide. Of this, 63.80±1.62% and 55.55±0.56% were recovered as the intact peptide, for SP and NKA, respectively. The various degradation products resulting from cleavage of SP or NKA, as estimated by the elution of radiolabeled product from RP-HPLC are shown in Fig. 6 as well as Tables I and II. In the absence of enzyme inhibitors when SP was the offered peptide, the major cleavage products recovered cochromatographed with SP 1-9, SP 1-7, SP 1-6, and the dipeptides Arg-Pro and Lys-Pro. When NKA was offered to lungs in the absence of enzyme antagonists the major products recovered co-chromatographed with methoxy-NKA, NKA 1-8, NKA 1-5, and the dipeptide His-Lys. The perfusates from lungs treated with thiorphan, SCH 32615, or TCBLCB groups showed an increase in the recovery of SPI 1-11 and a decrease in the formation of SP 1-7 and SP 1-6 relative to the recoveries in the absence of enzyme inhibitors. The amount of radioactivity recovered at the retention times of NKA 1-5 and NKA 1-8 was significantly lower after the treatment with thiorphan, SCH 32615 or TCBLCB compared with control or captopril groups (P < 0.01 for NKA 1-5 and P < 0.05 for NKA 1-8).
rr (24) . These data are in contrast to the effects observed when SP is offered to the lungs by the vascular route. In this case both NEP and ACE appear to have major roles limiting the airway effects of SP (22, 23) . It seemed likely that the difference between these two observations resulted from the fact that ACE is predominantly an endothelial enzyme while NEP is predominantly an epithelial enzyme. To test this hypothesis we used the tracheal superfused lung preparation described by Nucci and Moncada (26) . This preparation allows one to administer agents to the airway but not the pulmonary vascular surface while allowing for quantitation of both effects on airway tone and peptide recovery. In our preparation, the buffer entered the lungs via the trachea and was allowed to leave the lungs through numerous small holes made in the pleural surface. In preliminary studies we ascertained that when about 10 holes were made on the visceral pleural surface spread over the lung surface, formation of additional holes did not further lower tracheal perfusion pressure. This provided reasonable evidence that the Pao measurement reflected the resistance to flow through airways and was not influenced by the number or precise location of the pleural surface holes. We found that this preparation was very sensitive to mediators that cause an increase in airway smooth muscle tone. This included not only SP and NKA but also methacholine. In isolated contractile tissues it has been shown that guinea pig trachea is about 100 times more sensitive to NKA than to SP, while on parenchymal strips the effects of NKA and SP are similar (9) . Since the potency ofSP and NKA that we observed in the tracheal perfused lung (Figs. 1 and 2 ) are similar, our results suggest that these peptides have a more peripheral effect in this model.
We chose the concentrations of the various inhibitors used based on published literature values for effective enzyme inhibition. The concentration ofcaptopril used in our study, 3 MM, is sufficient to completely block SP degradation by purified ACE (16, 19) . 1 MM thiorphan almost completely inhibits NEP in in vitro preparations (15) . Although thiorphan is also a weak inhibitor ofACE, it is 30 times less potent as an ACE inhibitor than as a NEP inhibitor (28) . SCH 32615 is a novel NEP inhibitor (29) with little or no effect on ACE in concentrations up to 10 MtM. We also examined the effects ofa combination of four other peptidase inhibitors: bacitracin, leupeptin, chymostatin, and bestatin. The combination of bacitracin, leupeptin, and chymostatin has been shown to prevent SP degradation in rat brain and guinea pig gastrointestinal smooth muscle preparations (30) (31) (32) . Bestatin, was also used in the TCBLCB group in a concentration known to inhibit aminopeptidases (33, 34) .
We Our data demonstrate that both the effects on airway tone and recovery of offered peptide, be it SP or NKA, are enhanced in the presence of thiorphan or SCH 32615. In contrast there was no significant physiological effect of captopril alone, or any additional effect from TCBLCB compared to thiorphan alone. These data strongly suggest that when these two tachykinins are exposed predominantly to the airway epithelium that NEP is the major enzyme controlling their catabolism. Our data further provide insights into the metabolic fate of these two tachykinins when offered via the airways and thus exposed predominantly to the epithelium. In the absence of enzyme inhibitors both SP and NKA are extensively degraded, over 50% of offered peptide is degraded to inactive moieties . In the presence of enzyme antagonists the amount of intact peptide recovered increased significantly. This degradation was determined both using an ELISA that recognizes the carboxyl terminus of both peptides and by monitoring the recovery of infused radioactive peptides. The agreement between both methods of estimating recovered peptide provides strong evidence for both peptide breakdown and the inhibition of this breakdown by enzyme antagonists.
The profile of breakdown products obtained after HPLC analysis of lung perfusates obtained after tracheal infusion of
[3H]Prolyl2'4SP and '251-Histidyl'NKA was consistent with a major but not exclusive role for NEP in the metabolism of these peptides. It has been shown that NEP cleaves SP mainly between Gln6-Phe7, Phe7-Phe8, and Gly9-Leu'0 generating the (1-6), (1) (2) (3) (4) (5) (6) (7) , and (1-9) fragments (16, 35) . Cleavage of NKA by NEP is at the Ser5-Phe6 and Gly8-Leu9 positions, resulting in the (1-5) and (1-8) fragments (20) . The decrease in the formation of SP 1-6, SP 1-7, NKA 1-5, and NKA 1-8 observed after treatment of the lungs with NEP inhibitors further supports this conclusion. When the effects of multiple inhibitors were studied, i.e., TCBLCB, the amount of the dipeptide His-Lys formed from '251-Histidyl'NKA was decreased compared with thiorphan alone or SCH32615, although this effect did not result in a significant increase in total peptide recovery. It has been shown in a preparation of longitudinal muscle layer of guinea pig small intestine that NKA is a also a substrate for a bestatin sensitive aminopeptidase (36); inhibition of this aminopeptidase may account for the decreased recovery ofthis peptide.
In conclusion, our data demonstrate that NEP inhibition but not ACE inhibition significantly influences the effects of NKA and SP on airway smooth muscle when presented via the trachea. We also demonstrate that the cleavage of these tachykinins after airway infusion is consistent with the hypothesis that NEP, rather ACE, is the major enzyme controlling degradation of tachykinins that become available on the airway surface.
